The Dietary Approaches to Stop Hypertension (DASH) diet is established to reduce blood pressure and lower cholesterol, but the molecular mechanisms that mediate these cardiometabolic effects remain unclear. Prior randomized controlled feeding studies have identified a set of serum proteins whose circulating concentrations change in response to the DASH diet. Understanding whether those diet-responsive proteins play causal roles in downstream risk factors or disease outcomes could clarify pathways linking dietary patterns to long-term health.
The present work integrates molecular phenotyping from randomized dietary interventions with human genetics to evaluate potential mechanistic links between DASH-perturbed proteins and cardiometabolic disease. The authors started from 71 serum proteins previously reported to be altered by DASH in randomized feeding trials and then used genetic instruments to test for causal effects of those proteins on relevant risk factors and diseases.
To probe causality, the investigators conducted a series of Mendelian randomization analyses. The analyses used published genome-wide association study (GWAS) summary data as sources for genetic instruments and outcomes. The set of 71 proteins altered by the DASH diet was taken from earlier published work (Kim et al., J Am Heart Assoc. 2023). The authors explicitly state that all data produced in the study are available online and that published GWAS were used for genetic analyses.
Mendelian randomization leverages genetic variants associated with intermediate molecular traits (here, circulating protein levels) as instrumental variables to test whether those traits have causal effects on downstream clinical risk factors or disease endpoints. In this study, the approach aimed to identify proteins for which genetically predicted differences in levels influence cardiometabolic risk in a way that aligns with the direction of change induced by the DASH diet.
From the 71 DASH-responsive serum proteins, four proteins emerged with genetic evidence suggesting beneficial effects on risk factors in directions consistent with diet-induced changes. Those four proteins are ANGPTL3, INHBC, PCOLCE, and PLXNB2. The manuscript reports that these proteins had causal evidence of effects on relevant cardiometabolic risk factors that aligned with how their circulating concentrations changed when participants followed the DASH diet in randomized feeding studies.
The identification of these proteins provides candidate molecular mediators that could contribute to salutary effects of DASH on blood pressure, lipids, or other risk markers, although the specific risk factors tied to each protein are described at a summary level in the preprint abstract rather than as exhaustive per-protein effect estimates in the abstract text.
Beyond risk-factor links, the authors report genetic variant evidence for associations with clinical disease outcomes for two of the identified proteins. Missense variants in INHBC were associated with lower risk of coronary artery disease (CAD), and missense variants in PLXNB2 were associated with lower risk of type 2 diabetes (T2D). These genetic associations were directionally concordant with the changes in protein levels induced by the DASH diet, providing additional causal evidence that modulation of these proteins can influence disease risk.
The report frames these findings as complementary lines of evidence: randomized-intervention molecular phenotyping identifies diet-responsive proteins, while human genetics (including variant-level associations) supports causal roles for particular proteins in disease processes.
By combining randomized dietary intervention data with genetic causal inference methods, the study identifies candidate molecular regulators that could partly explain the long-term cardioprotective effects observed with the DASH diet. The concordance between diet-induced protein changes and genetically inferred effects on risk factors and disease strengthens the plausibility that modulating these circulating proteins may mediate some of the beneficial outcomes associated with DASH.
Specifically, identification of ANGPTL3, INHBC, PCOLCE, and PLXNB2 as proteins with supportive causal evidence provides targets for further mechanistic study. The missense variant associations for INHBC (CAD) and PLXNB2 (T2D) offer genetic anchors that can guide experimental follow-up and translational investigation to determine whether these proteins are actionable targets for prevention or therapy.
The manuscript is posted as a preprint on medRxiv and has not been peer reviewed; the authors and the medRxiv notice caution that the findings should not be used to guide clinical practice. The abstract and article indicate that the list of proteins altered by the DASH diet was taken from a previously published study, and that published GWAS were used for the Mendelian randomization analyses. The abstract does not provide detailed numerical results, effect estimates, or sensitivity analyses in the summary text; such details may be present in the full preprint and supplementary materials.
All data produced in the study are reported to be available online. Funding sources declared in the manuscript include multiple grants from the National Heart, Lung, and Blood Institute and the National Institute of Neurological Disorders and Stroke. The authors declare no competing interests and confirm compliance with ethical guidelines and participant consent procedures as described in the preprint.
Overall, the study illustrates an integrative strategy—linking randomized dietary intervention phenotyping with genetic causal inference—to nominate circulating proteins that may mediate the cardiometabolic benefits of the DASH diet. These nominated proteins warrant further mechanistic and clinical validation, ideally in peer-reviewed and experimentally confirmatory work.